Comparison
LL-37 vs. Vasopressin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
597562-32-8
no data
Molecular weight
4493.33 g/mol
1084.23 g/mol
Half-life
no data
no data
Sequence
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESno data
Mechanism of action
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Vasopressin
Vasopressin binds V1 receptors (vasoconstriction, raising vascular resistance) and V2 receptors (renal water reabsorption via aquaporin channels). This raises blood pressure and acts antidiuretically. Desmopressin is the V2-selective synthetic analog.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
0
of which in humans
1
0
Effects recorded
4
2
Open conflicts
1
0
Documented adverse events
0
1
Legal status
Full entries
Frequently asked questions
- What is the difference between LL-37 and Vasopressin?
- LL-37 is classified as "Research other", while Vasopressin is classified as "Research other". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Vasopressin: Vasopressin (arginine vasopressin, antidiuretic hormone/ADH) is a cyclic nonapeptide hormone that regulates water balance and vascular tone. As Vasostrict it is approved to raise blood pressure in vasodilatory shock. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Vasopressin?
- The highest available evidence level is "Human trial" for LL-37 and "Human RCT" for Vasopressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Vasopressin in Germany and the United States?
- Germany: LL-37 — Research only, Vasopressin — Prescription. United States: LL-37 — Research only, Vasopressin — Prescription. These are factual summaries with source and review date on the individual pages.